Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

There are limited patient-reported outcome (PRO) data tracking changes in toxicity in patients actively undergoing radiotherapy. Between 2015−2019, acute toxicity was prospectively measured in 698 patients undergoing a 5-week course of pelvic radiotherapy for gynecologic cancers using a weekly PRO questionnaire. Our questionnaire was able detect a pattern of onset and resolution of acute gastrointestinal (GI) and genitourinary (GU) toxicity in 27 out of 32 questions. Logistic regression analysis showed that increasing GI and GU toxicity at week 2 could predict for severe toxicity at week 5. However, due to a low number of severe events, univariate results could not be productively added to a multivariate model. We observed a >70% response rate for all sections of the questionnaire, except for questions on sexual and vaginal health, which had a 13% average response rate. By demonstrating that PRO data can be used to track acute toxicity during radiotherapy, there is a need to further examine how this tool may be implemented in the clinic to provide complex, adaptive care, such as early side effect management, and modifying radiation delivery in real-time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140006PMC
http://dx.doi.org/10.3390/curroncol29050270DOI Listing

Publication Analysis

Top Keywords

acute toxicity
12
patient-reported outcome
8
track acute
8
toxicity patients
8
patients undergoing
8
pelvic radiotherapy
8
radiotherapy gynecologic
8
gynecologic cancers
8
pro data
8
toxicity week
8

Similar Publications

Background: Tacrolimus is a commonly used immunosuppressant with well-defined side effects, including hypertriglyceridemia and hyperglycaemia. However, acute pancreatitis is still not widely recognized as an adverse event related to tacrolimus.

Case Presentation: A 60-year-old male was admitted to the intensive care unit with symptoms and signs of acute pancreatitis.

View Article and Find Full Text PDF

Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.

Front Nephrol

August 2025

Department of Nephrology, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.

Background: High-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity. Glucarpidase is the treatment of choice for MTX toxicity, but limited access in many countries may necessitate alternatives. We present the first reported adult case of combined high-flux hemodialysis (HFHD) and HA230 hemoadsorption for MTX clearance.

View Article and Find Full Text PDF

Methemoglobinemia is an uncommon yet potentially life-threatening condition that results from the oxidation of iron from the ferrous (Fe²⁺) to the ferric (Fe³⁺) state, rendering hemoglobin unable to effectively transport oxygen. This translates into a state of functional hypoxia despite adequate arterial oxygen tension. Among the various causes of acquired methemoglobinemia, recreational inhalation of alkyl nitrites, widely known as "poppers," is a notable but underrecognized trigger.

View Article and Find Full Text PDF

The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden.

Am J Hematol

September 2025

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.

View Article and Find Full Text PDF

Coagulant Moringa oleifera lectin (cMoL) is one of the compounds involved in the application of M. oleifera seeds for traditional water treatment methods. The present study highlights the new biotechnological potential of cMoL lectin as an antifungal agent against Cryptococcus neoformans B3501 and H99 and Cryptococcus gattii R265 strains.

View Article and Find Full Text PDF